7-Methyl-6,7,8,9,14,15-hexahydro-5H-benz[d]indolo[2,3-g]azecine: A New Heterocyclic System and a New Lead Compound for Dopamine Receptor Antagonists
Authors:
- 20 April 2000
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 43 (10) , 2079-2081
Abstract
Partially hydrogenated derivatives of the new heterocyclic ring systems benz[d]indolo[2,3-g]azecine and bisindolo[3,2-d][2,3-g]azecine were synthesized starting from lactones and amines via the described synthetic methods. In binding assays with rat striatal receptors, 7-methyl-6,7,8,9,14,15-hexahydro-5H-benz[d]indolo[2,3-g]azecine (LE 300) proved to be of high affinity for the D1 binding site (Ki = 0.08 nmol for displacement of [3H]SCH23390), being superior in this assay to standards such as butaclamol and SCH23390. This compound was characterized as a dopamine antagonist by conditioned avoidance response test with mice. Thus, LE 300 represents the lead of a new class of dopamine antagonists for future investigations.Keywords
This publication has 4 references indexed in Scilit:
- Drug Discovery and Evaluation1997
- Indoles XI. Syntheses and Stereochemistry of 5,6,7,8,13,13b-Hexahydrobenz[a]indolo[2,3-h]quinolizines and of 5,6,7,8,13,13b-Hexahydro-14H-bisindolo[3,2-a][2,3-h]quinolizineHETEROCYCLES, 1994
- Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1Nature, 1991
- Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylaseNature, 1990